Abstract
Neuronal cell dysfunction and death are cardinal features of Alzheimer disease and a great deal of effort is being expended not only to understand factors involved in the cause and progression of disease (i.e., disease initiators and propagators) but, ultimately, the precise mechanism by which neurons die (for want of a better word, the terminators). Understanding each and every component of the complex pathway that ultimately leads to disease (a clinical phenotype) is clearly of paramount importance for the development of effective therapeutic strategies. Of particular intrigue for many scientists, perhaps the more macabre among us, has been to decipher the final event - namely cell death. Broadly speaking, cell death falls into two categories, apoptotic and necrotic. The former, apoptosis, by definition, is a controlled event; thereby offering the potential for intervention, whereas necrosis is a more stochastic process. Since many of the propagators and exacerbators involved in Alzheimer disease are pro-apoptotic, it is not surprising that certain aspects of apoptosis are evident. However, it would be a mistake to call this apoptosis. In fact, as reviewed herein, the chronic course of disease together with the necessarily slow rate of neuronal death makes apoptotic cell death in Alzheimer disease a mathematical improbability. The numbers simply do not add up.
Keywords: Alzheimer disease, apoptosis, cell death, neurodegeneration
Current Alzheimer Research
Title: Apoptosis in Alzheimer Disease: A Mathematical Improbability
Volume: 3 Issue: 4
Author(s): Xiongwei Zhu, Arun K. Raina, George Perry and Mark A. Smith
Affiliation:
Keywords: Alzheimer disease, apoptosis, cell death, neurodegeneration
Abstract: Neuronal cell dysfunction and death are cardinal features of Alzheimer disease and a great deal of effort is being expended not only to understand factors involved in the cause and progression of disease (i.e., disease initiators and propagators) but, ultimately, the precise mechanism by which neurons die (for want of a better word, the terminators). Understanding each and every component of the complex pathway that ultimately leads to disease (a clinical phenotype) is clearly of paramount importance for the development of effective therapeutic strategies. Of particular intrigue for many scientists, perhaps the more macabre among us, has been to decipher the final event - namely cell death. Broadly speaking, cell death falls into two categories, apoptotic and necrotic. The former, apoptosis, by definition, is a controlled event; thereby offering the potential for intervention, whereas necrosis is a more stochastic process. Since many of the propagators and exacerbators involved in Alzheimer disease are pro-apoptotic, it is not surprising that certain aspects of apoptosis are evident. However, it would be a mistake to call this apoptosis. In fact, as reviewed herein, the chronic course of disease together with the necessarily slow rate of neuronal death makes apoptotic cell death in Alzheimer disease a mathematical improbability. The numbers simply do not add up.
Export Options
About this article
Cite this article as:
Zhu Xiongwei, Raina K. Arun, Perry George and Smith A. Mark, Apoptosis in Alzheimer Disease: A Mathematical Improbability, Current Alzheimer Research 2006; 3 (4) . https://dx.doi.org/10.2174/156720506778249470
DOI https://dx.doi.org/10.2174/156720506778249470 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Syntheses, Transformations and Pharmaceutical Applications of Kynurenic Acid Derivatives
Current Medicinal Chemistry Neuroglial Roots of Neurodegenerative Diseases: Therapeutic Potential of Palmitoylethanolamide in Models of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier
Current Drug Metabolism The Many Roles of Chemokine Receptors in Neurodegenerative Disorders: Emerging New Therapeutical Strategies
Current Medicinal Chemistry Meet Our Editorial Board Member:
Current Alzheimer Research A Needle-Free Approach for Topical Immunization: Antigen Delivery via Vesicular Carrier System(s)
Current Medicinal Chemistry Quantitative Structure-Activity Relationship Studies: Understanding the Mechanism of Tyrosine Kinase Inhibition
Current Enzyme Inhibition AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Protective Effects of Magnesium Sulfate on Radiation Induced Brain Injury in Rats
Current Drug Delivery Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Melanoma: The Radiotherapeutic Point of View; Review of the Current Literature
Reviews on Recent Clinical Trials Partial QSAR Analysis of Some Selected Natural Inhibitors of FAAH Suggests a Working Hypothesis for the Development of Endocannabinoid- Based Drugs
Current Drug Targets - CNS & Neurological Disorders Meet Our Editorial Board Member
Current Alzheimer Research Conference Report: (Annual Advances in Neurorestoratology: A Summary of IANR VI and 10th GCNN Conference, Bucharest, Romania, April 4-7, 2013)
CNS & Neurological Disorders - Drug Targets Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Serum Endocan, Neuron-Specific Enolase and Ischemia-Modified Albumin Levels in Newborns with Partial Blood Exchange Transfusion
Combinatorial Chemistry & High Throughput Screening The Role of Endothelin System in Cardiovascular Disease and the Potential Therapeutic Perspectives of its Inhibition
Current Topics in Medicinal Chemistry The Role of Neuronal Nicotinic Acetylcholine Receptors in Acute and Chronic Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders Molecular Mechanisms Underlying Specificity of Excitotoxic Signaling in Neurons
Current Molecular Medicine Cannabinoid Modulation of Neuroinflammatory Disorders
Current Neuropharmacology